Cambridge-based biotech company AIRNA has closed a $60 million financing round, bringing its total Series A funding to $90 million. Led by Forbion with new and existing investors, the funds will advance AIRNA’s lead RNA editing therapeutic into clinical trials and further develop its pipeline.